Substituted 11-phenyl-dibenzazepine compounds useful for the treatment or prevention of diseases characterized by abnormal cell proliferation

US6992079B2 · kind B2 · utility

Assignees

• President and Fellows of Harvard College · US
• Children's Medical Center Corporation · US
• NuChem Pharmaceuticals Inc. · CA

Inventors

• Carlo Brugnara · Newton, US
• Jose Halperin · Brookline, US
• Rudolf Fluckiger · Brookline, US
• Emile Bellott · Beverly, US
• Richard John Lombardy · Littleton, US
• John J. Clifford · Arlington, US
• Ying-Duo Gao · Murfreesboro, US
• Reem M. Haidar · Woburn, US
• Eugene Kelleher · Somerville, US
• Adel Moussa · Burlington, US
• Yesh P. Sachdeva · Concord, US
• Minghua Sun · Libertyville, US
• Heather N. Taft · Littleton, US
• Michael Zeldin · Cambridge, US

Key dates

• Filing date: Dec 7, 2001
• Grant date: Jan 31, 2006
• Expiry date: Dec 7, 2021

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D223/20
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides substituted 11-phenyl-dibenzazepine compounds which are specific, potent and safe inhibitors of mammalian cell proliferation. The compounds can be used to inhibit mammalian cell proliferation in situ as a therapeutic approach towards the treatment or prevention of diseases characterized by abnormal cell proliferation, such as cancer.